Alnylam Pharmaceuticals News

“I think there's certainly a resurgence in the interest in (chemical drugs)”

Mass High Tech: The Journal of New England Technology - by Ryan Mcbride Mass High Tech Sandie Allen Avila Therapeutics’ band of doctorate brothers include, from left, Russell Petter, co-founder and CSO ... via Mass High Tech

Comment?

THE REGION Alnylam Pharmaceuticals Inc.'s share rose 9 percent after the Cambridge biotechnology company posted a smaller-than-expected first-quarter loss and strong revenue growth. via Boston Globe

Comment?

May 12, 2008 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare ... via Med Ad News

Comment?

Swiss pharmaceutical giant Novartis AG has upped its ownership stake in Alnylam Pharmaceuticals Inc. via Boston Business Journal

Comment?

Amylin Pharmaceuticals Ammending Pact with Eli Lilly Concerning U.S. Marketing; Gilead Sciences CEO John Martin Takes on Additional Duties as Board Chairman; Novartis to Buy Another 214K Addtional Unregistered ... via ClipSyndicate

Comment?

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 213,888 unregistered shares of Alnylam's common ... via BioSpace

Comment?

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will report financial results for the first - 05/02/2008 - 04:00 PM MINNEAPOLIS-- --Urologix , Inc. via Business Wire

Comment?

“This new study continues to expand Alnylam's scientific leadership in the field of RNAi research as it represents continued understanding and refinement of our discovery process where - drug-like' properties of siRNAs can be readily achieved”

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced the publication of a study in the Journal of Interferon & Cytokine Research by scientists at Alnylam Europe , and collaborators, ... via BioResearch Online

Comment?

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Abstract The safe and effective delivery of RNA interference therapeutics remains an important challenge for clinical ... via Nature Biotechnology

Comment?

Isis Pharmaceuticals Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. via Freshnews

Comment?